Beijing Biotech
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS28
PHASE 3 / 2-30
RECRUITING28
READOUTS ≤12 MONTHS27
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| DUO-NK-NSCLC NCT07467863 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer; Advanced/Metastatic NSCLC | 48 | 2027-02-14 |
| SOLID-NK NCT07589530 |
P1/2 | Recruiting | Advanced Solid Tumors; Metastatic Solid Tumors | 60 | 2027-02-14 |
| DUAL-NK-BC NCT07486089 |
P1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer | 60 | 2027-02-14 |
| DUAL-NK-PDAC NCT07480928 |
P1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease | 42 | 2027-02-14 |
| EB-DART-NK01 NCT07744256 |
P1/2 | Recruiting | Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC | 60 | 2027-02-14 |
| DART-NK-SCLC NCT07480213 |
P1/2 | Recruiting | Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC | 60 | 2027-02-14 |
| DUAL-OV-CAR-NK NCT07480954 |
P1/2 | Recruiting | Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma | 36 | 2027-02-17 |
| EB-DUALNK-OV NCT07589543 |
P1/2 | Recruiting | Epithelial Ovarian Cancer; Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | 42 | 2027-03-14 |
| DUET-BTC NCT07641036 |
P1/2 | Recruiting | Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma | 30 | 2027-03-14 |
| EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells NCT07622940 |
P1/2 | Recruiting | Recurrent or Metastatic Esophageal Adenocarcinoma; Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease | 36 | 2027-03-14 |
| Dual-target CAR-NK cells NCT07510802 |
P1/2 | Recruiting | Breast Cancer (Advanced/Metastatic); HER2-positive Breast Cancer | 60 | 2027-03-14 |
| DUO-NK-NSCLC NCT07641023 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer; Advanced/Metastatic | 60 | 2027-03-14 |
| DUET-GEJ NCT07551362 |
P1/2 | Recruiting | Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma | 36 | 2027-03-14 |
| DUO-CRC-NK-111 NCT07589517 |
P1/2 | Recruiting | Colorectal Cancer; Metastatic Colorectal Adenocarcinoma | 48 | 2027-03-14 |
| DUAL-MESO-NK NCT07510815 |
P1/2 | Recruiting | Malignant Pleural Mesotheliomas | 36 | 2027-03-14 |
| DUET-HCC NCT07500220 |
P1/2 | Recruiting | Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer | 30 | 2027-03-14 |
| SELECT-SLE NCT07523542 |
P1/2 | Recruiting | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS; Lupus Nephritis | 24 | 2027-03-14 |
| DUAL-NK-NB NCT07502287 |
P1/2 | Recruiting | Relapsed Neuroblastoma; Refractory Neuroblastoma | 36 | 2027-03-14 |
| PRISM-NK NCT07510828 |
P1/2 | Recruiting | Advanced or Metastatic Solid Tumors | 60 | 2027-03-14 |
| ADAPT-HEM NCT07523555 |
P1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | 96 | 2027-03-14 |
| DUAL-HN NCT07617805 |
P1/2 | Recruiting | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC | 42 | 2027-03-14 |
| DUAL-NK-PDAC NCT07627711 |
P1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced | 42 | 2027-04-14 |
| SELECT-2CAR NCT07523529 |
P1/2 | Recruiting | Advanced Unresectable; Metastatic | 72 | 2027-04-14 |
| DUAL-NK RCC NCT07551349 |
P1/2 | Recruiting | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | 36 | 2027-04-14 |
| DUAL-OV-CAR-NK NCT07617753 |
P1/2 | Recruiting | Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma | 36 | 2027-06-14 |
| SELECT-NK-THYM NCT07598955 |
P1/2 | Recruiting | B2 Thymoma; Thymic Carcinoma | 36 | 2027-06-14 |
| DUET-MEL NCT07627698 |
P1/2 | Recruiting | Unresectable Melanoma; Metastatic Cutaneous Melanoma | 36 | 2027-06-14 |
| EB-DUO-CAR-NK-CEA/GCC (IV) NCT07462650 |
P1/2 | Recruiting | Colorectal Cancer Metastatic; Adenocarcinoma of Colon | 48 | 2027-12-21 |